Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan

European Journal of Pharmaceutical Sciences

Volumn 38, Issue 4, 2009, Pages 384-388

  Kummer, Oliver ^a   Haschke, Manuel ^a   Hammann, Felix ^a   Bodmer, Michael ^a   Bruderer, Shirin ^b   Regnault, Yann ^b   Dingemanse, Jasper ^b   Krähenbühl, Stephan ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

ACT 064992; ACT 132577; In vitro dissolution; Macitentan; Non peptide endothelin receptor antagonist; Pharmacokinetics

Indexed keywords

ACT 064992; ACT 132577; DRUG METABOLITE; ENDOTHELIN RECEPTOR ANTAGONIST; MACITENTAN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG SOLUBILITY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ABSORPTION; ADULT; CAPSULES; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; HUMANS; MALE; PYRIMIDINES; RECEPTORS, ENDOTHELIN; SOLUBILITY; SULFONAMIDES; TABLETS; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 70349807555     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2009.09.005     Document Type: Article

References (15)

1. Benedict N., Seybert A., and Mathier M.A. Evidence-based pharmacologic management of pulmonary arterial hypertension. Clin. Ther. 29 (2007) 2134-2153
2. Buggins T.R., Dickinson P.A., and Taylor G. The effects of pharmaceutical excipients on drug disposition. Adv. Drug Deliv. Rev. 59 (2007) 1482-1503
3. Channick R.N., Simonneau G., Sitbon O., Robbins I.M., Frost A., Tapson V.F., Badesch D.B., Roux S., Rainisio M., Bodin F., and Rubin L.J. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358 (2001) 1119-1123
4. Dingemanse J., and van Giersbergen P.L. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin. Pharmacokinet. 43 (2004) 1089-1115
5. Dunne A., O'Hara T., and Devane J. A new approach to modelling the relationship between in vitro and in vivo drug dissolution/absorption. Stat. Med. 18 (1999) 1865-1876 (discussion 1877)
6. Fattinger K., Funk C., Pantze M., Weber C., Reichen J., Stieger B., and Meier P.J. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther. 69 (2001) 223-231
7. Flaten G.E., Luthman K., Vasskog T., and Brandl M. Drug permeability across a phospholipid vesicle-based barrier. 4. The effect of tensides, co-solvents and pH changes on barrier integrity and on drug permeability. Eur. J. Pharm. Sci. 34 (2008) 173-180
8. Hoeper M.M. Drug treatment of pulmonary arterial hypertension: current and future agents. Drugs 65 (2005) 1337-1354
9. Iglarz M., Binkert C., Morrison K., Fischli W., Gatfield J., Treiber A., Weller T., Bolli M.H., Boss C., Buchmann S., Capeleto B., Hess P., Qiu C., and Clozel M. Pharmacology of macitentan, an orally active tissue targeting dual endothelin receptor antagonist. J. Pharmacol. Exp. Ther. (2008)
10. Krum H., Viskoper R.J., Lacourciere Y., Budde M., and Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan hypertension investigators. N. Engl. J. Med. 338 (1998) 784-790
11. Mwesigwa E., Basit A.W., and Buckton G. Moisture sorption and permeability characteristics of polymer films: implications for their use as barrier coatings for solid dosage forms containing hydrolyzable drug substances. J. Pharm. Sci. 97 (2008) 4433-4445
12. Nakano M. Effects of interaction with surfactants, adsorbents, and other substances on the permeation of chlorpromazine through a dimethyl polysiloxane membrane. J. Pharm. Sci. 60 (1971) 571-575
13. Rubin L.J., Badesch D.B., Barst R.J., Galie N., Black C.M., Keogh A., Pulido T., Frost A., Roux S., Leconte I., Landzberg M., and Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346 (2002) 896-903
14. Shah P., Jogani V., Mishra P., Mishra A.K., Bagchi T., and Misra A. In vitro assessment of acyclovir permeation across cell monolayers in the presence of absorption enhancers. Drug Dev. Ind. Pharm. 34 (2008) 279-288
15. Sidharta P.N., Dingemanse J., and van Giersbergen P.L.M. Pharmacokinetics and pharmacodynamics of the endothelin-1 receptor antagonist ACT-064992 in healthy human subjects. J. Clin. Pharmacol. 47 (2007) 1202